JP2012525134A - インフルエンザ赤血球凝集素の組成物とその使用 - Google Patents

インフルエンザ赤血球凝集素の組成物とその使用 Download PDF

Info

Publication number
JP2012525134A
JP2012525134A JP2012507784A JP2012507784A JP2012525134A JP 2012525134 A JP2012525134 A JP 2012525134A JP 2012507784 A JP2012507784 A JP 2012507784A JP 2012507784 A JP2012507784 A JP 2012507784A JP 2012525134 A JP2012525134 A JP 2012525134A
Authority
JP
Japan
Prior art keywords
ectodomain
protein
amino acid
influenza
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012507784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525134A5 (cg-RX-API-DMAC7.html
Inventor
マルティン バッハマン,
アンドレア イェゲルレーナー,
フィリップ サウダン,
Original Assignee
サイトス バイオテクノロジー アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトス バイオテクノロジー アーゲー filed Critical サイトス バイオテクノロジー アーゲー
Publication of JP2012525134A publication Critical patent/JP2012525134A/ja
Publication of JP2012525134A5 publication Critical patent/JP2012525134A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012507784A 2009-04-30 2010-04-30 インフルエンザ赤血球凝集素の組成物とその使用 Pending JP2012525134A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09159262.6 2009-04-30
EP09159262 2009-04-30
PCT/EP2010/055944 WO2010125202A1 (en) 2009-04-30 2010-04-30 Influenza hemagglutinin compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2012525134A true JP2012525134A (ja) 2012-10-22
JP2012525134A5 JP2012525134A5 (cg-RX-API-DMAC7.html) 2013-06-06

Family

ID=42790940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507784A Pending JP2012525134A (ja) 2009-04-30 2010-04-30 インフルエンザ赤血球凝集素の組成物とその使用

Country Status (9)

Country Link
US (1) US20120263743A1 (cg-RX-API-DMAC7.html)
EP (1) EP2424570A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012525134A (cg-RX-API-DMAC7.html)
CN (1) CN102573915B (cg-RX-API-DMAC7.html)
AU (1) AU2010243490A1 (cg-RX-API-DMAC7.html)
CA (1) CA2759873A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ596058A (cg-RX-API-DMAC7.html)
SG (1) SG175382A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010125202A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
KR20210151785A (ko) * 2019-03-13 2021-12-14 제너레이션 바이오 컴퍼니 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517632A (ja) * 2001-09-14 2005-06-16 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化:調製法および使用法
US20070042001A1 (en) * 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
WO2007068747A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US20070253982A1 (en) * 2006-03-07 2007-11-01 Langzhou Song Compositions that include hemagglutinin, methods of making and methods of use thereof
JP2009502789A (ja) * 2005-07-19 2009-01-29 ダウ グローバル テクノロジーズ インコーポレイティド 組み換えインフルエンザワクチン
JP2009513532A (ja) * 2003-07-10 2009-04-02 サイトス バイオテクノロジー アーゲー パッケージ化ウイルス様粒子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347973C (en) * 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
KR20050044316A (ko) * 2001-11-07 2005-05-12 사이토스 바이오테크놀로지 아게 호산구성 알레르기 질환 치료용의 il-5, il-13 또는에오탁신을 제시하는 항원 어레이
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
NZ554387A (en) * 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
PT1937301E (pt) * 2005-10-18 2015-09-14 Novavax Inc Partículas idênticas a vírus (vlps) da gripe funcionais
CU23576A1 (es) * 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
CN101394864A (zh) * 2006-03-07 2009-03-25 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517632A (ja) * 2001-09-14 2005-06-16 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化:調製法および使用法
JP2009513532A (ja) * 2003-07-10 2009-04-02 サイトス バイオテクノロジー アーゲー パッケージ化ウイルス様粒子
JP2009502789A (ja) * 2005-07-19 2009-01-29 ダウ グローバル テクノロジーズ インコーポレイティド 組み換えインフルエンザワクチン
US20070042001A1 (en) * 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
WO2007068747A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US20070253982A1 (en) * 2006-03-07 2007-11-01 Langzhou Song Compositions that include hemagglutinin, methods of making and methods of use thereof

Also Published As

Publication number Publication date
NZ596058A (en) 2013-08-30
EP2424570A1 (en) 2012-03-07
US20120263743A1 (en) 2012-10-18
WO2010125202A1 (en) 2010-11-04
SG175382A1 (en) 2011-12-29
CN102573915A (zh) 2012-07-11
CN102573915B (zh) 2015-02-18
CA2759873A1 (en) 2010-11-04
AU2010243490A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
US12605454B2 (en) Modified virus-like particles of CMV
RU2540871C2 (ru) Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
AU2004220549B2 (en) Influenza virus vaccine
RU2468034C2 (ru) Иммуногенные композиции и способы
AU2006224529B2 (en) Cat allergen fusion proteins and uses thereof
JP5714799B2 (ja) 機能的インフルエンザウイルス様粒子(vlp)
JP2008513035A (ja) Ap205のコートタンパク質と抗原性ポリペプチドとの融合タンパク質を含んでなるウイルス粒子
Park et al. Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
Sun et al. Toward innovative veterinary nanoparticle vaccines
CN101959526A (zh) 白介素-1偶联物在糖尿病治疗中的用途
CN102573915B (zh) 流感血凝素组合物及其用途
WO2025073874A1 (en) Vaccine composition comprising m2e nanoparticles and ha1 protein
ZA200506241B (en) Influenze virus vaccine
RU2852174C1 (ru) Рекомбинантная вакцина против вируса гриппа а человека и способ ее получения
WO2010122164A1 (en) VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
HK40077650A (zh) Cmv的修饰病毒样颗粒
HK40077650B (zh) Cmv的修饰病毒样颗粒
JP2025536956A (ja) 目的遺伝子rna製剤
BR122024008858A2 (pt) Uso de uma partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv), ou uma composição compreendendo a referida partícula no tratamento de uma doença, distúrbio ou condição em um animal ou ser humano
HK1255670B (zh) Cmv的修饰病毒样颗粒
BR112017008266B1 (pt) Partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv) e composição farmacêutica
BR122024008858B1 (pt) Uso de uma composição farmacêutica compreendendo uma partícula semelhante a vírus (vlp) modificada do vírus do mosaico do pepino (cmv) e um antígeno no tratamento de uma doença, distúrbio ou condição em um animal ou ser humano

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150526